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Emerging evidence suggests the gastrointestinal tract plays an important glucoregulatory role. In this
perspective, we first review how the intestine senses ingested nutrients, initiating crucial negative feedback
mechanisms through a gut-brain neuronal axis to regulate glycemia, mainly via reduction in hepatic glucose
production. We then highlight how intestinal energy sensory mechanisms are responsible for the glucose-
lowering effects of bariatric surgery, specifically duodenal-jejunal bypass, and the antidiabetic agents
metformin and resveratrol. A better understanding of these pathways lays the groundwork for intestinally
targeted drug therapy for the treatment of diabetes.Introduction
For the first time in the modern era, life expectancy of the current
generation is predicted to be lower than that of its predecessor,
due in large part to the rapidly rising rates of obesity over the past
half century. An overwhelming obesogenic environment, the
backdrop to a globally expanding western lifestyle, has led to a
‘‘diabesity’’ pandemic that represents a costly and urgent global
health crisis. Despite much medical and technological advance-
ment, not only does the pathogenesis of obesity and diabetes
remain poorly understood, but also modern society is in a unique
position where current treatments are being utilized despite not
having a clear grasp of the mechanisms of action. For example,
gastric bypass surgery is currently one of the most successful
options for reduction of body weight and improvements in
glucose homeostasis, despite the mechanisms involved remain-
ing relatively unknown. The success of gastric bypass surgery,
given it involves a rearrangement of the intestinal tract, and
several new promising gut-derived diabetes and obesity treat-
ments, such as GLP-1 analogs, highlight the role of the gastroin-
testinal (GI) tract in metabolic diseases. Indeed, the traditional
view of the GI tract as mainly having a macro- andmicro-nutrient
absorptive function has shifted to it being an important player
in many physiological systems, from immunity to metabolic
homeostasis.
The gut is a mediator between ingested nutrients and the
body, providing crucial information about the size and composi-
tion of a meal and initiating negative feedback pathways via a
gut-brain axis to control food intake (Cummings and Overduin,
2007). The metabolic role of the GI tract is recently extended,
as gut-derived signaling pathways induce thermogenesis, in-
crease energy expenditure, alter central food reward signaling,
promote insulin secretion, and lower hepatic glucose production
(HGP) (Baggio et al., 2004; Blouet and Schwartz, 2012; Scrocchi
et al., 1996; Tellez et al., 2013; Wang et al., 2008). Although the
relative clinical metabolic contribution of the gut-brain axiscompared to the traditional view that glucose homeostasis is
mediated via peripheral endocrine regulation (pancreatic insulin
and glucagon) remains to be thoroughly tested, the understand-
ing of these gut-derived pathways will lay the groundwork for
gut-targeted therapeutics for diabetes and obesity. In this
perspective, we highlight how intestinal nutrient sensing regu-
lates glucose homeostasis in a normal physiological setting
as well as mediates the beneficial glucose-lowering effects of
surgical and pharmacological therapies.
Intestinal Nutrient Sensing
Preabsorptive nutrients trigger complex and integrative gut-
brain negative feedback axes to prevent energy excess by
suppressing food intake and endogenous nutrient production.
Intestinal nutrients signal mainly through the release of GI pep-
tides, which act on central targets in an endocrine fashion, or
through local, paracrine action on nerve terminals innervating
the gut. Alternatively, nutrients themselves act alone, or in cohort
with gut peptides, to activate afferent neurons (Burcelin et al.,
2001; Darling et al., 2014) (Figure 1). Gut peptides are synthe-
sized in enteroendocrine cells (EECs) of the gut epithelial
mucosa. The EECs are exposed to the intestinal lumen on
their apical sides and secrete peptides from their basolateral
sides and are in close proximity to nerve endings expressing
gut peptide receptors, supporting local, paracrine signaling
(Richards et al., 2014). Classically, EECs are characterized by
the peptides that they produce. The proximal small intestine
contains I cells and K cells, which produce cholecystokinin
(CCK) and glucose-dependent insulinotropic hormone (GIP),
respectively, while the distal small intestine and colon contain
L cells, which produce glucagon-like peptide-1/2 (GLP-1/2),
oxyntomodulin and peptide YY (PYY). However, recent findings
indicate strong co-expression of these peptides within various
EECs throughout the small intestine, refuting the accepted clas-
sification system and suggesting that EECs may in fact beCell Metabolism 22, September 1, 2015 ª2015 Elsevier Inc. 367
Figure 1. Lipid- and Glucose-Sensing
Mechanisms in the Duodenum
In EECs, uptake of lipids, possibly via CD36, leads
to an accumulation of LCFA-CoA, which stimu-
lates CCK release via PKC-d. SGLT1 expressed on
EECs mediates glucose uptake, and upon activa-
tion by glucose, this transporter causesmembrane
depolarization, calcium influx, and gut peptide
release. Alternatively, we hypothesize that intra-
cellular metabolism of glucose to malonyl-coA
inhibits CPT-1-mediated uptake of LCFA-CoA into
mitochondria, which stimulates gut peptide
release in a similar fashion to that of lipid-induced
release of CCK by increasing cytosolic LCFA-CoA
levels. As opposed to direct EEC activation, in-
gested lipids passively diffuse into enterocytes
and are metabolized into chylomicrons. After
secretion, chylomicron-associated signaling mol-
ecules, such as Apo-AIV, stimulate gut peptide
secretion from adjacent EECs through unknown
mechanisms. ApoA-IV, Apolipoprotein A-IV; Ca2+,
calcium ion; CCK, cholecystokinin; CCK1-R,
cholecystokinin receptor 1; CD36, cluster of
differentiation 36; CNS, central nervous system;
CPT1, carnitine palmitoyltransferase 1; ENS;
enteric nervous system; GLP-1, glucagon like
peptide 1; GLP1-R, glucagon-like peptide 1 re-
ceptor; PKC-d, protein kinase C-d; LCFA,
long-chain fatty acid; Na+, sodium ion; SGLT1,
sodium-dependent glucose co-transporter; TG,
triglyceride.
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different peptides (Habib et al., 2012). Nonetheless, EECs are
activated by a variety of nutrient-dependent machineries that
trigger membrane depolarization, second messenger cascades,
and intracellular calcium elevation to stimulate gut peptide
release (Psichas et al., 2015) (Figure 1).
G protein-coupled receptors (GPCRs) such as fatty-acid-spe-
cific GPR40 and protein-sensitive CaSR colocalize with gut
peptides (Edfalk et al., 2008; Hirasawa et al., 2005; Liou et al.,
2011), as do electrogenic solute transporters such as sodium-
coupled glucose transporter 1 (SGLT-1) that trigger membrane
depolarization and calcium entry independent of intracellular
nutrient metabolism (Reimann et al., 2008). Nutrient uptake
and metabolism alternatively activate signaling pathways
involving long-chain fatty acid-CoA (LCFA-CoA) that trigger
CCK-mediated signaling pathways (Wang et al., 2008). Lipid
absorption by enterocytes and the subsequent packaging into
chylomicrons may be necessary for ingested lipids to stimulate
CCK and GIP release as well (Lo et al., 2007; Lu et al., 2012;
Raybould et al., 1998; Whited et al., 2005), while the release
of ApoA-IV may also be involved (Lo et al., 2007; Whited
et al., 2005). Once the gut peptides are secreted, they either
enter the circulation to act on central and peripheral targets
or communicate with the brain indirectly by acting locally on
afferent nerve terminals. In fact, both spinal and vagal afferents
innervate the lamina propria of the gut wall with their terminals in
close proximity of EECs. While spinal afferents are implicated
(Raybould and Ho¨lzer, 1992), most studies demonstrate vagal
afferent nerve terminals mediate the gut-brain negative feed-368 Cell Metabolism 22, September 1, 2015 ª2015 Elsevier Inc.back relays given that vagal afferents ex-
press CCK, GLP-1, PYY, and leptin re-
ceptors (Dockray, 2013).Gut peptides also activate vagal afferents indirectly, as neu-
rons of the enteric nervous system (ENS) relay nutrient-derived
signals to the CNS (Ritter, 2011) and respond to GLP-1 and
CCK (Amato et al., 2010; Patterson et al., 2002; Richards et al.,
2014), although the ENS is classically known to control intestinal
function (Costa et al., 2000). One study even suggests that fatty
acids act directly onGPR40 expressed on vagal afferents to sup-
press food intake (Darling et al., 2014), bypassing gut peptide
secretion and adding to the complexity of intestinal nutrient
sensing. Nevertheless, activation of this vagal gut-brain axis is
vital for nutrient-triggered negative feedback, since treating the
gut with anesthetics, neurotoxins, or vagotomy abolishes the
effects of intestinal nutrients on food intake and glucose regula-
tion (Schwartz, 2011). Vagal afferent fibers terminate in the nu-
cleus tractus solitarius (NTS) of the hindbrain, and antagonism
of N-methyl-D-aspartate (NMDA) receptors in the NTS reverses
the effects of intestinal nutrients or CCK to lower food intake or
suppress HGP (Cheung et al., 2009; Wang et al., 2008; Wright
et al., 2011). Intestinal CCK-mediated activation of NTS NMDA
receptors leads to MAPK-ERK1/2 signaling and phosphorylation
of synapsin I in hindbrain neurons (Campos et al., 2012), and
through unclear mechanisms, these neurons act as a relay for
vagal gut-derived signals to control food intake or suppress
HGP via the hepatic vagal efferent (Wang et al., 2008).
While the role of nutrient-induced feedback in the control of
food intake is extensively studied and reviewed elsewhere (Cum-
mings and Overduin, 2007), more recent work has established
a glucoregulatory role of intestinal nutrient sensing. Given that
themajority of nutrients are absorbed in the duodenum, the small
Figure 2. Jejunal-Sensing Mechanisms
following DJB Surgery
Increased nutrient influx results in the activation
of nutrient-sensing pathways in the jejunum that
trigger gut peptide release and the activation of a
gut-brain-liver axis to lower glucose production.
Exclusion of the duodenum results in increased
influx of gastric leptin into the distal small intes-
tine, which activates signaling pathways that
ultimately trigger vagal afferent firing to lower
HGP. DJB, duodenal-jejunal bypass; Ob-Rb,
functional long form leptin receptor; PI3K, phos-
phoinositide-3-kinase; ACS, acetyl CoA synthe-
tase; LCFA-CoA, long-chain fatty acid-CoA;
SGLT1, sodium glucose transporter 1; GLP-1,
glucagon-like peptide 1; PYY, peptide YY; CCK,
cholecystokinin.
Cell Metabolism
Perspectiveintestine likely represents the major site of direct intestinal
nutrient sensing, consistent with possessing the highest level
of vagal innervation throughout the intestines (Berthoud et al.,
1995). While jejunal nutrient-sensing mechanisms exist (Figure 2)
and act through conserved mechanisms to those present in the
duodenum, it is apparent that more distal nutrient sensing only
becomes relevant in the context of surgical rearrangement of
the gut (see Bariatric Surgery), while duodenal nutrient-sensing
mechanisms are necessary for normal glucose homeostasis
during physiological re-feeding conditions (Breen et al., 2012;
Cheung et al., 2009; Kokorovic et al., 2011).
Duodenal Gut-Brain Axis
Acute intraduodenal infusion of a lipid emulsion lowers HGP
through a gut-brain-liver neuronal axis in healthy rodents, which
is dependent upon intestinal CCK-1 signaling (Cheung et al.,
2009; Wang et al., 2008). This glucose-lowering effect requires
uptake of LCFA and subsequent intracellular esterification to
LCFA-CoA by acyl-CoA synthetase (ACS) (Wang et al., 2008).
While the involvement of fatty acid transporters in the glucoregu-
latory effects of intraduodenal lipids has not been tested, a likely
role of fatty acid transporter cluster of differentiation 36 (CD36)
is presented given that CD36/ mice exhibit a reduced satiety
response as well as reduced CCK release in response to intesti-
nal lipids (Schwartz et al., 2008; Sundaresan et al., 2013)
(Figure 1). Furthermore, the glucose-lowering effect of LCFAs
is mediated by the activation of duodenal protein kinase C
(PKC)-d, which is expressed in rodent and human duodenal
mucosa (Breen et al., 2011; Kokorovic et al., 2011), consistent
with studies reporting that PKC-d mediates LCFA-induced
CCK secretion from STC-1 cells (Chang et al., 2000; Takahashi
et al., 2000). Although the downstream signaling events of
PKC-d remain unclear, this glucose-lowering LCFA/LCFA-
CoA/PKC-d axis requires activation of duodenal CCK-1 recep-
tors (CCK-1R) (Breen et al., 2011; Cheung et al., 2009).
The CCK-1R is a GPCR, possessing domains for Gs and Gq
(Cawston and Miller, 2010). Although studies highlight that
CCK-1R activation induces Gq-dependent pathways in various
cell types (Cawston and Miller, 2010; Matozaki and Williams,
1989), CCK-1R activation increases cyclic AMP levels as well
(Wu et al., 1997), while both phospholipase C and protein kinase
A (PKA) are necessary for CCK to activate central vagal afferent
terminals (Rogers and Hermann, 2008). Similarly, intestinalCCK-1R signaling via PKA mediates intestinal CCK to increase
vagal afferent firing and lower HGP (Rasmussen et al., 2012),
consistent with the fact that CCK-1R is localized on vagal
afferent terminals that innervate the duodenal mucosa (Raybould
et al., 1988). Further, activation of the duodenal lipid-PKA
pathway triggers NMDA receptor transmission in the NTS to
lower HGP via the hepatic vagal branch (Rasmussen et al.,
2012). These results indicate that duodenal lipid sensing regu-
lates HGP via a local LCFA/LCFA-CoA/PKC-d/CCK/
CCK1R/PKA signaling axis, which activates a gut-brain-liver
neuronal axis to lower HGP in healthy rodents (Coˆte´ et al., 2014).
Interestingly, the necessity for LCFA-CoA accumulation and
activation of PKC-d in the gut to lower HGP mirrors the
glucose-lowering effect of mediobasal hypothalamus nutrient
sensing (Duca and Yue, 2014). Carnitine palmitoyltransferase-1
(CPT-1) regulates the transport of LCFA-CoA into the mitochon-
dria for b-oxidation, such that inhibiting hypothalamic CPT-1
elevates cytoplasmic LCFA-CoA levels, thereby triggering a
brain-liver axis that inhibits HGP (Obici et al., 2003). It is therefore
likely that inhibiting CPT-1 in the gut increases intestinal LCFA-
CoA levels and thus triggers the aforementioned gut-brain-liver
axis to lower HGP (Figure 1); however, this remains to be inves-
tigated.
In the brain, malonyl-CoA inhibits CPT-1 activity and elevates
hypothalamic LCFA-CoA to lower HGP (Caspi et al., 2007;
He et al., 2006). The ability of glucose in the hypothalamus to
suppress HGP is reversed when the conversion of acetyl-CoA
to malonyl-CoA is inhibited via activation of AMP-dependent
protein kinase (AMPK) (Yang et al., 2010). Thus, malonyl-CoA
is a converging molecule through which lipid and glucose
sensing in the brain lowers HGP. Although the role of duodenal
glucose-sensing in the regulation of HGP has not been investi-
gated, a likely model exists where intestinal glucose is metabo-
lized to malonyl-CoA, contributing to the accumulation of
LCFA-CoA and triggering a PKC-d/CCK-mediated gut-brain
axis to lower HGP (Figure 1). However, it is to be noted that
glucose is more recognized to release GLP-1 instead of CCK
(Richards et al., 2014).
The idea that intracellular metabolism of glucose leads to gut
peptide release implicates a role of SGLT-1, which is responsible
for glucose uptake in the intestinal epithelium (Dobbins et al.,
2015). In fact, generation of SGLT1/ mice reveals not onlyCell Metabolism 22, September 1, 2015 ª2015 Elsevier Inc. 369
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release of GLP-1 (Gorboulev et al., 2012). Interestingly, recent
studies report non-metabolizable substrates of SGLT-1 stimu-
late GLP-1 release (Moriya et al., 2009; Reimann et al., 2008),
suggesting that activation of SGLT-1 per se leads to GLP-1
release independent of glucose cellular metabolism (Figure 1).
Further, GLUT activity, but not SGLT-1, mediates intracellular
glucose concentrations, while the electrogenic property of
SGLT-1 activation is sufficient to cause membrane depolariza-
tion and Ca2+ entry in L cells (Parker et al., 2012). Future studies
are clearly required to dissect the mechanisms of preabsorptive
glucose sensing in the intestine with regards to intracellular
glucosemetabolism versus cell surface SGLT1 activation in vivo.
Given the short half-life of GLP-1 in circulation (Holst, 2007)
and GLP-1 receptors (GLP-1Rs) are expressed in the nodose
ganglia that contain the cell bodies for vagal afferents innervating
the intestine and hepatoportal vein (Nakagawa et al., 2004), it is
likely that GLP-1 acts in the gut or portal region to stimulate a
gut-brain metabolic axis (Hayes et al., 2010). GLP-1Rs in the
hepatoportal vein are necessary for portal glucose and GLP-1
signaling to regulate glucose tolerance (Burcelin et al., 2001;
Vahl et al., 2007), while portal infusion of GLP-1 induces a vagal
hepatopancreatic reflex as well (Nakabayashi et al., 1996). The
expression of GLP-1R protein in the portal vein has been docu-
mented, but the specificity of the antibody was not properly
established (Vahl et al., 2007; Panjwani et al., 2013), thus ques-
tioning whether GLP-1R in the nodose ganglia is actually trans-
ported to the afferent terminals innervating the portal vein (and
possibly GI tract). On the other hand, GLP-1R expression in
vagal afferents is, after all, possible given that the receptor for
another L-cell-derived peptide, PYY, is synthesized in the
nodose ganglia and axonally transported (Koda et al., 2005). In
addition, GLP-1R-positive neurons are in close proximity to in-
testinal GLP-1-secreting cells (although it was not determined
if these were vagal afferent or non-vagal) (Richards et al.,
2014). Future studies are warranted to further characterize the
vagal distribution of GLP-1R expression.
Physiological Role of Intestinal Nutrient Sensing
It is important to reiterate again that intestinal nutrient-sensing
mechanisms exhibit a physiological glucoregulatory role. For
example, in line with the fact that the anorectic effect of ingested
nutrients is abolishedwith the administration of a CCK-1R antag-
onist in rats (Bellissimo and Anderson, 2003) and humans (Beg-
linger et al., 2001), normal glucose homeostasis is disrupted with
intraduodenal CCK-1R antagonist infusion or in Otsuka Long-
Evans Tokushima fatty (OLEFT) rats (which lack the CCK-1R)
during a fasting-refeeding protocol independent of changes in
food intake (Cheung et al., 2009). Inhibition of duodenal PKC-d,
which lies upstream of CCK-1R signaling in lipid-induced
lowering of HGP, similarly impairs regulation of plasma glucose
levels during the same fasting-refeeding paradigm (Breen
et al., 2011; Kokorovic et al., 2011). These observations are
strengthened by the fact that OLETF rats are hyperglycemic
and hyperinsulinemic (Kawano et al., 1992), although both the
impairment of CCK-1R signaling and the genetic susceptibility
of the Long-Evans strain (Yamada et al., 2012) may contribute
to these metabolic disturbances, as CCK-1R knockout (KO)
F344 rats and mice are normoglycemic (Bi et al., 2007; Blevins
et al., 2009). The clinical glucoregulatory role of CCK signaling370 Cell Metabolism 22, September 1, 2015 ª2015 Elsevier Inc.remains to be assessed, but such a role has been implicated in
the glucose-lowering effect of bile acid sequestrant treatment
in people with impaired fasting glucose (Marina et al., 2012).
Similarly, portal infusion of exendin-9 impairs glucose toler-
ance in a pseudo-fasting-refeeding paradigm where fasted rats
are anaesthetized and given a gastric bolus of glucose (Vahl
et al., 2007). While exendin-9 increases blood glucose levels
compared to saline injection following an OGTT in rats with vagal
common hepatic branch ablation (eliminates vagal afferents of a
hepatoportal origin), rats with a subdiaphragmatic vagotomy
(eliminates all vagal afferents innervating the peritoneal cavity)
do not respond to exendin-9 following OGTT (Hayes et al.,
2011), suggesting that while vagal afferent fibers of the hepato-
portal region may contribute to glycemic control, it is the vagal
afferents innervating the intestine that are required for the phys-
iological glucoregulatory effect of endogenous GLP-1 action.
Whether GLP-1 activates vagal afferents innervating the intes-
tine or portal vein in humans remains unknown. However, there
is evidence that vagal GLP-1 signaling may play a role in glucose
metabolism in humans.
Vagotomy in patients with duodenal ulcers impairs glucose
tolerance following an oral, but not intravenous, glucose toler-
ance test (Humphrey et al., 1975). Two follow-up studies in pa-
tients with truncal vagotomy and pyloroplasty indicate that this
effect may be due to GLP-1 vagal signaling, as these patients
exhibit impaired GI -mediated glucose disposal following an
OGTT in the face of increased GLP-1 levels (hypothesized to
be due to the pyloroplasty), and these individuals have reduced
insulinotropic and glucagonostatic effects following exogenous
GLP-1 administration (Plamboeck et al., 2013a, 2013b). These
studies suggest that vagal GLP-1 action improves oral glucose
tolerance via a gut-brain-mediated secretion of insulin and/or
glucagon, while GLP-1 could also directly lower HGP in humans
during the pancreatic clamp (Seghieri et al., 2013), possibly via a
gut-brain-liver axis. Not all studies in humans demonstrate a role
for the vagus in glucose homeostasis (Corssmit et al., 1995), and
although non-vagal neural signaling (spinal afferents) may
mediate intestinal sensing mechanisms in humans, this is yet
to be tested, together with the fact that only a few studies
demonstrate a nutrient-sensing role of the spinal afferents in
rodents (Raybould and Ho¨lzer, 1992). Lastly, it is to be acknowl-
edged that direct activation of the GLP-1R expressed in the
pancreas (Campbell and Drucker, 2013) may also underlie the
ability of exendin-9 to disrupt glucose tolerance in rodents
(Kolligs et al., 1995; Wang et al., 1995) and humans (Edwards
et al., 1999; Salehi et al., 2008) following an OGTT or a meal.
In summary, small intestinal nutrient-sensing mechanisms
trigger hormonal pathways to control metabolic homeostasis.
We next address whether these respective mechanisms could
contribute to the metabolic benefits of bariatric surgery.
Bariatric Surgery
Bariatric surgery is currently the most successful treatment for
sustained body weight reduction in obese individuals. The
most effective and widely performed surgical technique is the
Roux-en-Y gastric bypass (RYGB), which involves the formation
of a small upper gastric pouch to which a roux jejunal limb is
anastomosed. This procedure creates alimentary, biliopancre-
atic, and common limbs, thus excluding most of the stomach
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malabsportive components. RYGB provides significant and sus-
tained weight loss, with up to 30% weight loss maintained for
over 10 years (Karlsson et al., 2007); however, the benefits of
RYGB extend well beyond weight loss and include metabolic
benefits (Sjo¨stro¨m et al., 1999). In the case of diabetes remission,
the effects on glucose control appear independent of weight
loss, as dramatic improvements in these parameters occur
rapidly, usually within 1 week, before any significant weight
loss has been achieved (Schauer et al., 2003). Consequently,
bariatric surgery is now being referred to as a ‘‘metabolic sur-
gery’’ (Rubino, 2013) and is currently being explored as a treat-
ment for type 2 diabetes (T2D) with some indication that surgical
treatment results in greater glucose control than conventional
medical therapy (Ikramuddin et al., 2013; Mingrone et al.,
2012; Schauer et al., 2012). Although RYGB improvements
were originally hypothesized to be due to its restrictive and
malabsorptive capacity, a large body of evidence argues against
this (Miras and le Roux, 2013; Stefater et al., 2010; Thaler and
Cummings, 2009) and suggests that the main beneficial effects
of RYGB are due to alterations in GI biology (Manning et al.,
2015). Given the gross anatomical rearrangement of the GI tract,
it is a safe assumption that the intestine exhibits vast and rapid
metabolic adaptations that coincide with the early success of
bariatric surgery.
To better tease out these intestinal adaptive mechanisms
underlying the efficiency of RYGB, duodenal-jejunal bypass
(DJB) surgery was developed, an experimental procedure that
mimics the intestinal alterations present in RYGB by surgically
excluding the duodenum and proximal jejunum while preserving
the stomach (Wittgrove et al., 1996). Although DJB does not elicit
the same weight loss effects as RYGB, it has similar gluco-reg-
ulatory effects (Hu et al., 2014; Jiao et al., 2013; Rubino et al.,
2006; Salinari et al., 2014). Non-obese diabetic DJB rats show
improved glucose homeostasis, independent of changes in
food intake or body weight, as early as 1 week after the proce-
dure and persisting for 9 months (Rubino and Marescaux,
2004; Speck et al., 2011). DJB also lowers glucose in non-obese
(Cohen et al., 2012a; Cohen et al., 2007) ormild-obese (Lee et al.,
2010) humans with T2D. Given that the rearrangement of the GI
tract is the same for DJB and RYGB, improvements in glycemia
following small bowel manipulations are hypothesized to be due
to either a foregut or hindgut hypothesis. The foregut hypothesis
suggests that excluding the proximal intestine diminishes a path-
ophysiological rise in an unknown ‘‘anti-incretin’’ signal that nor-
mally serves to counteract incretin-mediated insulin secretion
and prevent hypoglycemia (Salinari et al., 2014). On the other
hand, the hindgut hypothesis proposes glycemia improvements
are due to alterations in the chemosensory capacity of the distal
small intestine now exposed to an increased flux of unabsorbed
nutrients and the subsequent release of gut peptides and
communication to important metabolic organs. Indeed, gut hor-
mone signaling has been extensively investigated in mediating
the beneficial effects of bariatric surgery (Scott and Batterham,
2011), given that RYGB increases the number of gut-peptide-ex-
pressing EECs (Mumphrey et al., 2013) and, as such, postpran-
dial gut peptide secretion (Madsbad et al., 2014).
One such candidate is GLP-1, as the increase in circulating
GLP-1 levels following both RYGB (Chambers et al., 2011; Jime´-nez et al., 2013; Rodieux et al., 2008; Salehi et al., 2011) and DJB
(Imoto et al., 2014; Kindel et al., 2009) have led many investiga-
tors to examine the role of GLP-1 signaling in the post-surgical
effects of RYGB andDJB procedures. Exaggerated postprandial
GLP-1 profiles occur as early as 2 days post-surgery (le Roux
et al., 2007), persist as long as 10 years post-surgery (Dar
et al., 2012), and are elicited by previously established sub-
threshold caloric loads (i.e., before surgery, meal size provides
minimal stimulation of GLP-1 secretion, but after surgery,
same meal size induces a significant rise in postprandial GLP-
1) (Yan et al., 2014). Improvements in glucose tolerance following
RYGB correlates with sensitivity to GLP-1 signaling, as only rats
that respond to administration of exendin-4, a GLP-1R agonist,
before surgery exhibit improved glucose tolerance following
RYGB despite similar post-surgical body weight loss among
responders and non-responders (Habegger et al., 2014b). In hu-
mans, poor weight loss in patients that received gastric bypass
is associated with attenuated postprandial GLP-1 response,
although changes in glycemic control were not measured (Dirk-
sen et al., 2013; le Roux et al., 2007), while improvements in
glucose tolerance following RYGB (Chambers et al., 2011) and
DJB (Imoto et al., 2014; Kindel et al., 2009) are abolished with
exendin-9 administration. However, the involvement of GLP-1
in the beneficial effects of these procedures has been argued
against, as DJB is not associated with changes in incretin
signaling (Salinari et al., 2014), while inhibition of GLP-1 signaling
has no effect on glycemia following RYGB (Jime´nez et al., 2013;
Shah et al., 2014) or in an operation similar to DJB (Troy et al.,
2008). Further, GLP-1RKOmodels show no impairment in glyce-
mic control (Mokadem et al., 2014). Thus, although compensa-
tion for the loss of GLP-1R function (in KO animals) could be a
precipitating factor, improvement in glycemia following RYGB
and DJB appears not to be dependent on GLP-1 signaling; how-
ever, it is possible that other gut peptides in the distal intestine
may play a role.
As such, PYY has been implicated, as plasma PYY levels are
also increased following RYGB (le Roux et al., 2006, 2007;
Rodieux et al., 2008) and DJB (Imoto et al., 2014; Liu et al.,
2012a; Liu et al., 2012b). While there is evidence for a causal
link between PYY signaling and weight loss in both humans
(le Roux et al., 2007;Morı´nigo et al., 2008) and rodents (Chandar-
ana et al., 2011), studies investigating the role of PYY in the
resolution of T2D are relatively lacking. A recent study, however,
associates PYY with improved GLP-1 response and glucose
tolerance (Chandarana et al., 2013) and suggests that studies
aiming to investigate the role of PYY in the anti-diabetic effect
of bariatric surgery are warranted.
Given the complexity and redundancy of postprandial intesti-
nal signaling mechanisms, it is likely that the beneficial effects
of gastric bypass cannot be solely attributed to changes in the
action of a single peptide, but more likely from beneficial integra-
tive adaptations involving an improved concerted action of gut
sensing and signaling pathways. Thus, it was hypothesized
that the success of bariatric surgery is partly due to the overall
effectiveness of jejunal nutrient-sensing mechanisms, as intraje-
junal infusion of glucose and lipids lowers HGP through a
neuronal network as observed in the duodenum (Breen et al.,
2012) (Figure 2). To evaluate the role of jejunal nutrient sensing
in mediating the improvements in glycemia following bariatricCell Metabolism 22, September 1, 2015 ª2015 Elsevier Inc. 371
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insulin-deficient, streptozodocin (STZ)-induced uncontrolled
diabetic model and in Bio-breeding (BBdp) rats, an autoimmune
type 1 diabetic rat. DJB rapidly (in 2 days) lowers plasma glucose
concentrations in STZ-induced and BBdp diabetic rodents, and
this glucose lowering is independent of changes in insulin con-
centrations, food intake, and body weight (Breen et al., 2012).
This is in line with the fact that most studies demonstrate
weight-loss-independent glycemic effects of DJB (Cohen
et al., 2012b; Hu et al., 2013) and that DJB rapidly improves
glucose tolerance but does not enhance insulin sensitivity (Jiao
et al., 2013; Kindel et al., 2009). Importantly, during fasting-
refeeding experiments, inhibition of jejunal glucose- and fatty-
acid-sensing mechanisms via intrajejunal infusion of SGLT-1
inhibitor phlorizin or ACS inhibitor triacsin C, respectively, dis-
rupts glucose homeostasis compared to vehicle infusions (Breen
et al., 2012) (Figure 2). Thus, activation of jejunal nutrient-sensing
mechanisms mediates the rapid glucose-lowering effect of DJB,
likely via lowering of HGP through vagal signaling (Jiao et al.,
2013). Similarly, improvement in glucose regulation following
entero-gastro anastomosis (a variant of DJB) is mediated by a
gut-brain neuronal axis that lowers glucose production (Troy
et al., 2008).
It should be noted that while normalization of glucose con-
centrations in diabetic rats following DJB is associated with a
rise in plasma GLP-1 levels, the effect in BBdp rats is indepen-
dent of changes in GLP-1 (Breen et al., 2012); thus, the
functional relevance of GLP-1 in mediating the rapid glucose-
lowering effect induced by DJB remains to be clarified. As
such, we have identified that another GI peptide, leptin, may
be responsible for the rapid glucose-lowering effect observed
during DJB (Rasmussen et al., 2014) (Figure 2). Although the
main contributor to circulating leptin is adipocytes, leptin is
also secreted by gastric chief cells in response to nutrients
(Bado et al., 1998) and is subsequently detected in duodenal jui-
ces (Guilmeau et al., 2003). In fact, direct leptin infusion into the
jejunum activates jejunal leptin receptor-PI3K signaling and
lowers HGP via a neuronal network, while direct blockade of
jejunal leptin receptor signaling disrupts glucose homeostasis
in DJB-diabetic rodents during refeeding (Rasmussen et al.,
2014). Although the specific intestinal cell type mediating the ef-
fect of leptin following DJB is not determined, recent evidence
indicates that leptin receptors on vagal afferents innervating
the intestine, but not intestinal epithelial cells themselves (de
Lartigue et al., 2014; Rajala et al., 2014), are important for the
development of obesity and possibly hyperglycemia. Thus, it
is likely that jejunal leptin is directly activating the vagus nerve
by binding to the leptin receptor localized on the afferents
innervating the intestine (Burdyga et al., 2002).
Inhibition of jejunal leptin signaling does not disrupt glucose
homeostasis to the same extent as seen in STZ-induced diabetic
rodents who receive sham surgery (Rasmussen et al., 2014),
indicating that complete normalization of blood glucose levels
by DJB likely involves an integration of leptin signaling with
both interactive and non-complimentary mechanisms. For
example, leptin enhances CCK signaling via activating vagal
leptin receptor (Barrachina et al., 1997; de Lartigue et al.,
2010), while leptin may also mediate the anorectic effect of
GLP-1 (Williams et al., 2006). Therefore, improved jejunal nutrient372 Cell Metabolism 22, September 1, 2015 ª2015 Elsevier Inc.sensing (mentioned above) possibly via CCK or GLP-1 secretion
may interact with jejunal leptin signaling to synergistically lower
blood glucose levels (Figure 2), supporting a hypothesis of an
improved action of multiple mechanisms in nutrient sensing.
However, it is also possible that some of the rapid glucose
normalizing effects of bariatric surgery are independent of jejunal
nutrient and leptin signaling.
One candidate contributor to the effects of bariatric surgery
is bile acid. Both RYGB (Kohli et al., 2013; Patti et al., 2009)
and duodenal exclusion (via duodenal-endoluminal sleeve that
blocks nutrient-tissue interaction in the duodenum) (Habegger
et al., 2014a) alter the quantity and composition of bile acids,
possibly through increased FGF19 signaling (Gerhard et al.,
2013); however, early (1 week) improvement in glucose homeo-
stasis is not associated with changes in bile acids or FGF19
(Jørgensen et al., 2015). Interestingly, vertical sleeve gastrec-
tomy (VSG), which involves roughly 80% removal of the stom-
ach while maintaining intestinal integrity, results in sustained
weight reduction and improved glycemic control (Seeley
et al., 2015), which is attributed not to changes in GLP-1 (Wil-
son-Pe´rez et al., 2013), ghrelin (Chambers et al., 2013), apo-IV
(Pressler et al., 2015), or MC4R (Mul et al., 2012) signaling,
but due to enhanced bile acid-FXR signaling (Ryan et al.,
2014). It is interesting that despite leaving the intestine intact,
VSG induces substantial enteroplasticity (Seeley et al., 2015),
demonstrating the potential for future therapeutics to influence
intestinal signaling mechanisms without intestinal surgical
alteration. Of note, most studies examining improvement in
glucose homeostasis following VSG are relatively long-term,
with one study even demonstrating no difference in meal-
stimulated glucose tolerance 1 week post-operatively (Peterli
et al., 2009). Thus, a better understanding of how rapid and
long-term anti-diabetic mechanisms adapt and interact with
one another following bariatric surgery could provide crucial
drug targets that may ultimately replace the need for surgical
intervention.
Pharmacological Relevance of Small Intestinal Energy
Sensory Mechanisms
Research demonstrating the intestinal tract is a salient contrib-
utor to both the physiological control of glucose metabolism
and the beneficial outcomes of bariatric surgery highlights the
gut as a potential therapeutic target. Indeed, several GLP-1
analogs are currently on the market for treatment of diabetes,
namely exenatide and liraglutide, which share 53% and 97%
homology with native GLP-1, respectively, and have proved suc-
cessful in improving glycemia (Madsbad et al., 2008). The mech-
anisms detailing the glucose-lowering effect of these drugs have
been extensively reviewed elsewhere (Campbell and Drucker,
2013), but it should be noted that in addition to a major incretin
effect, evidence suggests GLP-1R agonists also lower HGP to
control glucose metabolism (Abu-Hamdah et al., 2009), possibly
via the aforementioned gut-brain-liver pathway. This opens up
the possibility that other antidiabetic compounds that improve
glucose homeostasis by lowering HGP may be gut mediated.
In fact, a potential contributing role of small intestinal energy
sensors to the HGP- and glucose-lowering effects of metformin
and resveratrol has been recently evaluated (Coˆte´ et al., 2015;
Duca et al., 2015) (Figure 3).
Figure 3. Metformin and Resveratrol
Activate Duodenal Energy Sensors to Lower
Glucose Production via a Neuronal Network
Metformin activates a duodenal AMPK-depen-
dent, while resveratrol activates a duodenal
SIRT1-dependent, neuronal pathway to lower
HGP. AMPK, AMP-activated protein kinase;
SIRT1, sirtuin 1; NTS, nucleus tractus solitarius.
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Metformin is the first-line therapeutic for T2D and lowers plasma
glucose levels by inhibiting HGP (Foretz et al., 2014). Metformin
was originally postulated to lower GP by indirectly activating he-
patic AMP-activated kinase (AMPK), an intracellular energy
sensor via increased AMP levels resultant from inhibition of the
mitochondrial respiratory chain complex 1 (Owen et al., 2000).
However, recent literature has challenged the conventional belief
that metformin inhibits HGP via hepatic AMPK activation,
demonstrating that metformin suppresses glycolytic enzymes
in mice lacking liver AMPKa1/a2 (Foretz et al., 2010), antago-
nizes hepatic glucagon action (Miller et al., 2013), and/or alters
mitochondrial and cytosolic redox states (Madiraju et al.,
2014). Adding to, and complimenting, these described potential
direct hepatic actions, preabsorptive metformin is recently
documented to lower HGP in high-fat diet (HFD)-obese and dia-
betic rats via a neuronal network (Duca et al., 2015) (Figure 3),
consistent with the fact that intraduodenal metformin, as
opposed to intraportal or intravenous, infusion results in the
greatest effect on lowering blood glucose levels (Stepensky
et al., 2002). Specifically, preabsorptive metformin lowers HGP
by activating duodenal mucosal AMPK and triggering GLP-1R
(Duca et al., 2015), strengthening the hypothesis that an increase
of GLP-1 levels mediates the antidiabetic effect of metformin
(Maida et al., 2011; Vardarli et al., 2014).
Although it remains to be tested, it is plausible that metformin
acts directly on GLP-1-secreting cells localized in the duodenum
(Habib et al., 2012), since metformin-induced reduction of HGP
is attenuated with intraduodenal infusion of GLP-1 receptor
antagonist exendin-9 (Duca et al., 2015), despite metformin
inducing GLP-1 release via a neuronal-hormonal reflex (Mulherin
et al., 2011). Metformin may increase duodenal AMPK activity
in the GLP-1-secreting cells, which induces calcium influx
and GLP-1 release, similar to the fact that AMPK activates
neuropeptide Y neurons via calcium influx (Kohno et al., 2011).
Another AMPK activator, AICAR, increases GLP-1 (Maida
et al., 2011; Mulherin et al., 2011), further suggesting that
AMPK activation mediates GLP-1 release in EECs. FutureCell Metabolism 22, Sstudies are warranted to elucidate the
underlying mechanisms of metformin-
mediated increases in GLP-1 levels.
Of note, the physiological contribution
of duodenal AMPK in the glucose-
lowering effect of metformin is docu-
mented in an experimental setting where
the pancreatic-euglycemic clamp is not
performed. Specifically, diabetic rats
with virally duodenal-targeted molecular
inhibition of AMPK activity fail to exhibitlower plasma glucose levels in the first 60 min following an
intragastric bolus injection of metformin, as compared to rats
with intact duodenal AMPK (Duca et al., 2015), indicating a phys-
iological glucose-lowering ability of duodenal metformin-AMPK
signaling. Further, while both sets of rats (with inhibited or intact
duodenal AMPK activity) exhibit overall reduction in plasma
glucose levels 3 hr after the metformin gastric injection, the
total drop in glucose in the rats with duodenal AMPK inhibition
was only50%of that of rats with intact duodenal AMPK activity
(Duca et al., 2015). Thus, the preabsorptive metformin-duodenal
AMPK-induced reduction in plasma glucose levels has a potent
and sustained contribution to the overall suppression of plasma
glucose following metformin treatment.
Resveratrol
Metabolic improvements associated with activation of AMPK in
various tissues involve an interactive dependency with another
energy sensor, the NAD+-dependent deacetylase sirtuin 1
(SIRT1) (Canto´ et al., 2009; Coˆte´ et al., 2015; Feige et al., 2008;
Fulco et al., 2008; Hou et al., 2008; Lan et al., 2008; Price
et al., 2012). Resveratrol, a polyphenolic compound synthesized
in plants, activates SIRT1, exerting caloric mimetic effects such
as reducing plasma glucose levels and improving insulin sensi-
tivity (Baur et al., 2006; Lagouge et al., 2006; Park et al., 2012;
Price et al., 2012; Timmers et al., 2011), although the effective-
ness in humans is debated (Bitterman and Chung, 2015). The un-
derlying mechanisms remain elusive. In this regard, it is recently
documented that intraduodenal infusion of resveratrol activates
duodenal SIRT1 and triggers a vagal gut-brain neuronal axis
to improve hypothalamic insulin sensitivity to lower HGP in
HFD-fed and diabetic rodents (Coˆte´ et al., 2015) (Figure 3).
This effect of resveratrol was duodenal AMPK dependent as
well (Coˆte´ et al., 2015), and the possibility that duodenal SIRT1
is activated by the ability of AMPK to increase NAD+ (Canto´
et al., 2009; Feige et al., 2008; Fulco et al., 2008) remains to be
tested.
Potential drugs targeting duodenal AMPK- and SIRT1-depen-
dent pathways would add to an expanding list of potential ‘‘gut-
targeted’’ treatments for diabetes. For example, although DPP-4eptember 1, 2015 ª2015 Elsevier Inc. 373
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direct action of endogenous GLP-1 on b-cells, a very low oral
dose of sitagliptin (a DPP-4 inhibitor) selectively reduces intesti-
nal DPP-4 activity and is sufficient to improve glucose tolerance
in association with increased vagal nerve activity in diet-induced
obese rodents (Waget et al., 2011). Two recent independent
studies also demonstrate that intestinal-specific acting com-
pounds, such as the anti-inflammatory agent 5-aminosalicylic
acid (Luck et al., 2015) and a gut-restricted FXR agonist (Fang
et al., 2015), improve whole-body metabolic homeostasis in
obese rodents.
In summary, emerging studies are indicating that sensory
mechanisms in the small intestine are pharmacologically and
therapeutically relevant.
Conclusion
The traditional islet/insulin-centered model for glucose homeo-
stasis has been recently challenged by the glucoregulatory
importance of both the brain and insulin-independent mecha-
nisms. Thus, a two-compartment model whereupon diabetes
develops from a cooperative failure of both islet- and brain-
centered-glucoregulatory systems is proposed (Schwartz
et al., 2013). However, as highlighted in this perspective,
intestinal nutrient sensing plays a physiological role in the
maintenance of blood glucose levels by regulating HGP, and
these signaling pathways are rapidly diminished with high-fat
feeding (Cheung et al., 2009; Wang et al., 2008). Perhaps early
perturbations in intestinal physiology during high-fat feeding
precede the deleterious effect of a HFD on the glucoregulatory
function of both the brain and pancreas, although this hypoth-
esis remains to be examined. Nonetheless, as evidence
continues to emerge, we propose that the GI tract should
be incorporated into this 21st century model of glucose ho-
meostasis, remotely activating brain-centered glucoregulatory
systems.
There is controversy as to whether central glucoregulatory
pathways are physiologically relevant in larger mammals (dogs
and humans), in which some suggest glucose homeostasis is
largely attributed to direct hepatic insulin action (Ramnanan
et al., 2012), although recent studies challenge the overall glyce-
mic importance of hepatic insulin signaling (O-Sullivan et al.,
2015; Titchenell et al., 2015) and demonstrate that the brain
can potently increase glucose effectiveness, which is insulin
independent (Morton et al., 2013). Furthermore, in humans,
oral diazoxide, a KATP channel activator, decreases HGP, likely
via KATP channel activation in the brain, consistent with the fact
that, in rodents, central blockade of the KATP channel abolishes
the effect of oral diazoxide (Kishore et al., 2011). Additionally, in
type 1 diabetics, 6 months of diazoxide treatment improves
metabolic control independent of changes in insulin production,
possibly due to the aforementioned mechanism (Radtke et al.,
2010), while intranasal insulin delivery reduces HGP in healthy
men (Dash et al., 2015). The potential mechanisms for the brain
to control HGP are reviewed elsewhere (Carey et al., 2013), but
it should be noted that intranasal insulin delivery in humans
increases hypothalamic activity, parasympathetic tone, and
whole-body insulin sensitivity, indicating a potential hypotha-
lamic-vagal efferent axis regulating glucose homeostasis (Heni
et al., 2014). This is consistent with both rodent findings (Pocai374 Cell Metabolism 22, September 1, 2015 ª2015 Elsevier Inc.et al., 2005) and the fact that activation of muscarinic receptors
inhibits HGP in humans (Boyle et al., 1988). Although hepatic
denervation in humans with liver transplants does not impair
glucose homeostasis (Perseghin et al., 1997), the loss of para-
sympathetic drivemay be off-set by the lack of opposing sympa-
thetic activity (Cailotto et al., 2008). Clearly, while rodent studies
and recent clinical data depict the glucoregulatory role of the
brain- and gut-brain-liver axis, future clinical studies exploring
these pathways are warranted.
Perhaps more crucial than outlining the physiological impact
of these axes is the pressing need for the development and bet-
ter understanding of successful antidiabetic treatment options.
This perspective highlights the vital role of the small intestinal
energy sensory mechanisms in the anti-diabetic effect of
bariatric surgery, metformin, and resveratrol. Interestingly, one
common link between these surgical and pharmacological inter-
ventions is alterations in the gut microbiota (Dao et al., 2011;
Shin et al., 2014; Zhang et al., 2009). As the gut microbiota
rapidly adapts to its environment, shifts in the bacterial commu-
nities of the GI tract may represent the initial trigger for the
metabolic improvements observed following these surgical
and pharmacological treatments, indicating the potential signif-
icance of being able to manipulate the gut microbiota. As we
better understand how gut microbial-host crosstalk could
mediate host metabolic changes, we may one day be able to
identify or create specific bacterial therapy that could target
intestinal energy sensory mechanisms that regulate glucose ho-
meostasis as those described throughout the review, and pre-
liminary evidence suggests microbiota transplant could be a
successful antidiabetic treatment (Vrieze et al., 2012). Overall,
the GI tract represents a promising avenue for the development
of successful targeted therapeutic options for the treatment of
diabetes.
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